tiprankstipranks
NuCana Reports Breakthrough in Resistant Melanoma Treatment
Company Announcements

NuCana Reports Breakthrough in Resistant Melanoma Treatment

Nucana (NCNA) has released an update.

Pick the best stocks and maximize your portfolio:

NuCana plc showcased positive results from its Phase 2 study of NUC-7738 in combination with pembrolizumab, offering hope for metastatic melanoma patients who have not responded to PD-1 inhibitor therapy. The treatment led to prolonged progression-free survival and disease control in 75% of participants, demonstrating a potential new therapeutic avenue for resistant melanoma cases. With a favorable safety profile, the dual therapy could redefine the standard of care for this challenging patient demographic.

For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNucana Reports Third Quarter Loss Amid R&D Investments
TheFlyNuCana reports Q3 EPS (GBP 0.07) vs (GBP 0.13) last year
TipRanks Auto-Generated NewsdeskNuCana’s NUC-3373 Shows Promise in Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App